Over 160 people. 
One shared standard  of execution.

Meri is a former life sciences and healthtech venture capital investor, with an MSc in Biology from the University of Oxford. Serving on the boards of health and biotech companies, he saw CROs repeatedly fail to deliver clinical trials on time and on budget. After participating in a COVID-19 vaccine trial, he saw how fragmented integrated technology, poor patient experience and operational problems at sites cascaded up to the cost and timeline overruns he experienced as an investor. He founded Lindus to fix these problems and provide a more accountable, predictable model for research.

Michael was previously a Special Adviser to the UK Prime Minister, where he advised on a range of issues including life sciences. Before serving in government, he worked at McKinsey & Company and L.E.K. Consulting, predominantly on commercialization and M&A in the healthcare space. His time in government during the pandemic showed him how much trial delivery depended on fragmented, outdated infrastructure, and convinced him the industry needed a fundamentally different operating model; without this none of the groundbreaking advances in understanding human biology will ever benefit patients. He founded Lindus to fix these bottlenecks.

Gemma leads R&D of CitrusTM, Lindus’ AI-native operating system. She is a technology executive who has spent her career building and scaling engineering teams. Before Lindus she spent three years as a Principal Software Engineering Manager at Microsoft, leading teams of up to 30 engineers on Telecoms products in Azure. Prior to that she spent 23 years at Metaswitch Networks, advancing from Software Engineer to Senior Software Engineering Manager. She holds a BA in Mathematics and a Diploma in Computer Science from the University of Cambridge, and is an active advocate for women in technology.

Heather has over 30 years of experience in clinical operations, spanning clinical site, biotech, and CRO environments. She co-founded Highline Sciences, an oncology-focused CRO, and served as its COO, scaling the company from seven employees to over 100 before its acquisition by Tempus AI. She remained as COO of Tempus Compass, integrating technology with clinical operations and supporting the company through its IPO. Her earlier career includes senior roles at Precision For Medicine, SynteractHCR, and Novella Clinical (now IQVIA), across oncology, immunology, and neurology.

Luke is a physician with nearly three decades of clinical and leadership experience. He was Lindus employee number three. He previously served as CEO of Omnes Healthcare, delivering dermatology, ENT, diagnostic, and general practice services to the NHS, and directed clinical governance at UnitedHealth Group (Optum). He continues to practise as a GP alongside his role at Lindus, bringing frontline clinical perspective to the medical oversight of every trial. He trained at the Universities of Oxford and Cambridge, and holds an MBA from Durham University.

Veronica Vu is a clinical data executive driving next-generation data strategy and delivery across clinical trials. She began in clinical data management for interventional medical device studies and progressed to leading data delivery functions at Verily, Faro, and Lindus. At Lindus, she oversees deployment, data management, and biostatistics for the full trial portfolio, driving quality and automation at the intersection of clinical operations and product. Her work spans decentralized trial platforms, data-driven trial design, and scalable, standards-based delivery, with a focus on improving data quality, automation, and operational efficiency to modernize how clinical trials are designed and executed.

Cristy has over a decade of experience scaling technology-enabled clinical research and real-world evidence businesses. She most recently served as Vice President of Life Sciences at Topography Health, expanding the company's pharma and biotech relationships and channel partnerships with major CROs. She previously led large-scale real-world evidence programs at Evidation Health, and began her career in healthcare finance and clinical research. She holds an MBA from UC Berkeley's Haas School of Business and a BA in Biology from Amherst College.

Rich is a clinical research executive with over two decades in oncology trial management. He built his foundation during an 11-year tenure at PPD, progressing from Research Associate to Project Manager across global oncology programmes. He went on to lead immuno-oncology project management at IQVIA Biotech, then held senior roles at Novella Clinical (now IQVIA), KCR, Vial, and ICON Biotech. His career spans Phase I through Phase IV oncology studies, with particular depth in immuno-oncology clinical strategy and global trial oversight.

Malcolm has over 25 years of international experience in life sciences and health technology. At GSK and Haleon, he served as Chief Growth and Innovation Officer, leading commercial innovation and strategic partnerships.

Gaby spent four years as Commercial Director at Papier, a direct-to-consumer startup, where she was part of the leadership team that scaled the business fivefold in people and revenue through Series A to C. She holds an MChem in Chemistry from the University of Oxford.

Hannah joined Lindus from Accurx, a healthcare communications platform, where she led market strategy, growth, and go-to-market operations. Before that, she was a Lead Consultant at Newton Europe, specializing in operational improvement across healthcare and the public sector. She holds an MEng in Aerospace Engineering from the University of Cambridge.